t-cells

Alemtuzumab is a humanized monoclonal antibody against CD52 an antigen found on the surface of normal and malignant lymphocytes.

Atezolizumab is an antibody inhibitor, a humanized monoclonal antibody, IgG1, which targets PD-L1 and blocks the interaction of PD-L1 with PD-1. Atezolizumab has antitumor activity and promotes T-cells to attack tumor cells.

Nivolumab is a monoclonal antibody, a humanized IgG4 antibody to PD-1. Nivolumab has antitumor activity and is used in the treatment of melanoma, non-small cell lung cancer, renal cell carcinoma and others.

Pembrolizumab (MK-3475) is a humanized monoclonal antibody inhibiting the PD-1 receptor and the first in the class of agents called the HER2 dimerization inhibitors that impairs the ability of HER2 to bind to other members of the HER family.

ABP-102 (CT P72) is a tetravalent IgG1-[L]-scFv bispecific t-cell adduct (BiTE) that acts as a CD3 modulator and selective HER2 modulator for the selective targeting of HER2 overexpressing tumors. ABP-102 showed cytotoxicity in HER2-overexpressing models of breast and gastric cancers, while significantly decreasing activity against HER2 low level cells, twice as effective as rununmotamab.

Cibisatamab is a T-cell bispecific antibody that acts as a T-cell splicer.Cibisatamab targets carcinoembryonic antigen (CEA) on cancer cells and CD3 on T-cells, and triggers T-cell killing when the CEA on the surface of the cancer cells ranges from intermediate to high levels.Cibisatamab may be used to study solid cancers such as colorectal cancer.

Mosunetuzumab (BCT-4465A) is a humanized antibody based on immunoglobulin G1 that targets CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used to study relapsed or refractory (R R) B-cell non-Hodgkin lymphoma (B-NHL) and refractory follicular lymphoma.

Odronextamab, a fully human, hinge-stabilized IgG4-based bispecific antibody, targets CD3 receptors on T cells and CD20 receptors on B cells [1].

Vudalimab, a fully humanized bispecific monoclonal antibody, effectively inhibits both PD-1 and CTLA-4 immune checkpoint receptors. This dual action facilitates the selective activation of T-cells targeting tumors.

Foralumab (NI-0401) is an orally available human anti-CD3 monoclonal antibody that downregulates NKG7 and increases TGFB1 and GIMAP7 expression in T cells from COVID-19 subjects for the study of COVID-19 infection.

Rolinsatamab is a fully humanized selective monoclonal antibody that is a potent dual inhibitor of IL-4 and IL-13. Rolinsatamab chimeric antigen receptor sequence T cells. Rolinsatamab can be used to prevent and treat immune diseases.

Mogamulizumab (KW-0761) is a monoclonal antibody targeting T cell CC chemokine receptor 4. It exhibits anticancer activity by eliminating tumor cells through antibody-dependent cytotoxicity (ADCC) and can be used in the study of cancer, adult T-cell leukemia lymphoma (ATLL), and cutaneous T-cell lymphoma (CTCL).

Toralizumab (IDEC-131), a humanized monoclonal antibody (mAb) directed against CD40L (CD154), consists of human gamma 1 heavy chains and human kappa light chains. Specifically targeting CD40L on T cells, it inhibits CD40 signaling, acting as an immunosuppressive agent with potential applications in systemic lupus erythematosus (SLE) research [1] [2].

Gresonitamab (AMG 910), a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody, specifically targets CD3-positive T cells and CLDN18.2-expressing tumor cells, offering potential research applications in adenocarcinoma [1].

Bavunalimab (Anti-Human CTLA4xLAG3), a bispecific human monoclonal antibody targeting CTLA-4 and LAG-3, activates T cells in NSG mice and is utilized in cancer research [1].

Neihulizumab (ALTB-168), an immune checkpoint agonistic antibody, targets and binds to human CD162 (PSGL-1), resulting in the downregulation of activated T-cells. It is utilized in research aimed at treating steroid-refractory acute graft-versus-host disease (SR-aGVHD), psoriasis, psoriatic arthritis, and ulcerative colitis [1].

Tepoditamab (MCLA-117) is a bispecific monoclonal antibody targeting CLEC12A on myeloid cells and CD3 on cytotoxic T cells. As a myeloid differentiation antigen, CLEC12A allows the compound to eliminate AML leukemia progenitor and stem cells through T cell-mediated proliferative lysis, making it valuable in acute myeloid leukemia (AML) research [1].

Teclistamab (JNJ-64007957) is a human bispecific monoclonal antibody targeting the CD3 receptor expressed on the surface of t-cells and the b-cell maturation antigen (BCMA) expressed on the surface of malignant multiple myeloma b-lineage cells for the treatment of relapsed and refractory multiple myeloma.

Talquetamab (JNJ-64407564) is a GPRC5D bispecific antibody for multiple myeloma (MM) that induces T-cell-mediated killing of GPRC5-expressing MM cells through T-cell recruitment and activation, demonstrating antitumor activity.

Efalizumab, a novel potent regulator of T cells, is a humanized LFA-1 α subunit (CD11a) monoclonal antibody. Efalizumab has inhibitory effects on T cell activation, skin T cell transport, and T cell adhesion to keratinocytes, and can be used to study plaque psoriasis and psoriatic arthritis.

Vibecotamab (XmAb14045) is a potent bispecific antibody that targets CD123 and CD3, promoting T cell-mediated elimination of CD123-expressing cells. It exhibits antitumor properties and is used in studies on acute myeloid leukemia [1].

Vepsitamab (AMG 199) is an anti-MUC17 CD3 BiTE antibody that targets CD3 on T cells and MUC17 on tumor cells, promoting targeted tumor cell destruction and stimulating T cell activation and proliferation [1].

Tebotelimab (MGD-013) is a bispecific antibody targeting PD-1 and LAG-3, classified as a human IgG4κ dual-affinity re-targeting (DART) molecule. It has binding affinities with EC50 values of 1.65 nM for PD-1 and 0.41 nM for LAG-3 on NS0 cells. The compound inhibits PD-1 PD-L1, PD-1 PD-L2, and LAG-3 HLA (MHC-II) interactions, as well as PD-1 signaling pathways, thereby reinvigorating exhausted T-cell responses and bolstering antitumor immunity [1] [2] [3].

Cevostamab (BFCR4350A; RG6160; RO7187797), a humanized IgG1-based bi-specific antibody (BsAb), specifically targets the membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells and CD3 on T cells. It enhances synapse formation and augments T cell-mediated killing of MM tumor cells [1] [2].